[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stemi\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stemi":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,44,76,114,137,169,191,223,256,279,301,323,346,377,403,425,458,477,499,518,539,560,586,611],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100641201","intravascular-ultrasound-guidance-versus-angiography-guidance-in-patients-with-st-segment-elevation-myocardial-infarction-100641201",false,"NCT07616024","Intravascular Ultrasound guidaNce versuS angIoGrapHy Guidance in Patients With ST-segment Elevation Myocardial Infarction","Intravascular Ultrasound guidaNce versuS angIoGrapHy Guidance in Primary percuTaneous Coronary Intervention for Patients With ST-segment Elevation Myocardial Infarction","INSIGHT-STEMI","Inclusion criteria\n\n1. Patients diagnosed with acute ST-segment elevation myocardial infarction (STEMI) who have an indication for emergency interventional therapy;\n2. Subjects who are eligible to undergo primary percutaneous coronary intervention (PCI);\n3. Subjects or their authorized family members voluntarily agree to participate in the clinical trial and sign the written informed consent form;\n4. The IVUS catheter is expected to pass through the target lesion to complete the examination.\n\nExclusion Criteria\n\n1. Patients with cardiogenic shock or severe heart failure (Killip class IV);\n2. Patients who have previously undergone coronary artery bypass grafting (CABG);\n3. Patients with coma or disturbance of consciousness;\n4. Patients who are expected to be intolerant to long-term antiplatelet therapy;\n5. Pregnant women;\n6. Life expectancy \\\u003C 1 year;\n7. Currently participating in another drug\u002Fdevice clinical trial and not having reached the primary endpoint;\n8. Poor compliance, expected to be unable to complete follow-up.","ALL","18 Years",{"count":20,"type":21},2488,"ESTIMATED","INTERVENTIONAL",[24],"NA","STEMI represents the subtype of ACS with the worst prognosis, associated with high mortality and an elevated risk of complications. The use of IVI guidance holds the potential to reduce the incidence of MACE. In previous studies, there has been limited research on intravascular imaging in the context of primary revascularization procedures for STEMI, and no large-scale cohort study has compared the differences in clinical outcomes between IVI-guided and angiography-guided primary revascularization. Therefore, we conducted this large-scale randomized controlled trial to compare IVI-guided primary PCI versus coronary angiography-guided primary PCI in patients with STEMI.",[27,28],"STEMI","PCI",[27,28,30],"IVUS","NOT_YET_RECRUITING","2026-06-16",{"date":34,"type":35},"2026-06-18","ACTUAL",{"date":37,"type":21},"2026-06-01",{"date":39,"type":21},"2032-12-31",{"name":41,"class":42},"Shanghai Zhongshan Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100637367","phase-2-effect-of-guanxinning-tablet-on-coronary-microcirculation-after-primary-percutaneous-coronary-intervention-in-patients-with-acute-myocardial-infarction-100637367","NCT07621107","Effect of Guanxinning Tablet on Coronary Microcirculation After Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction","A Randomized Explorative Pre-trial of the Effect of Guanxinning Tablet on Coronary Microcirculation After Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction","Inclusion Criteria:\n\n* Age between 18 and 80 years (gender is not restricted).\n* STEMI diagnosed for the first time and with an onset time within 12 hours. (According to the \"Chinese Guidelines for the Diagnosis and Treatment of Acute ST - Segment Elevation Myocardial Infarction 2019\" and the fourth - edition \"Global Definition of Myocardial Infarction\" criteria, myocardial infarction refers to acute myocardial injury \\[serum cardiac troponin (cTn) increases and\u002For decreases, and at least once is higher than the upper limit of the normal value (the 99th percentile of the upper limit of the reference value)\\], along with clinical evidence of acute myocardial ischemia, including: (1) Symptoms of acute myocardial ischemia; (2) New ischemic electrocardiogram changes; (3) New pathological Q - wave; (4) New imaging evidence of viable myocardial loss or abnormal wall segmental motion; (5) Coronary artery thrombosis confirmed by coronary angiography, intracavitary imaging examination, or autopsy.)\n* Successfully received PPCI treatment (assessed by visual inspection or quantitative coronary angiography, with residual stenosis of the target lesion \\\u003C 20% after stent implantation or \\\u003C 50% after simple balloon dilation, and forward TIMI blood flow ≥ grade 2).\n* Signed a written informed consent form.\n\nExclusion Criteria:\n\n* Cardiogenic shock with poor response to vasoactive drugs; or uncontrolled acute left - heart failure or pulmonary edema; uncontrolled malignant arrhythmia.\n* LVEF \\\u003C 40%.\n* Currently using nicorandil, other Chinese patent medicines, and Chinese herbal decoctions, etc.\n* Unable to undergo CMR examination for various reasons.\n* Expected to be unable to complete 6 - month treatment with Guanxinning Tablets.\n* Contraindications or allergies to Guanxinning Tablets.\n* Suspected or confirmed hereditary cardiomyopathy (such as hypertrophic, dilated, obstructive cardiomyopathy, cardiac amyloidosis, hemochromatosis cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, etc.).\n* Active or chronic liver disease.\n* Renal insufficiency (eGFR \\\u003C 60ml\u002Fmin\u002F1.73m²).\n* History of previous cerebral hemorrhage.\n* History of alcohol or drug abuse.\n* Known active infection, or severe hematological, metabolic, or endocrine dysfunction.\n* Patients who have received systemic steroid or cyclosporine treatment in the past 3 months.\n* Active malignant tumor.\n* Life expectancy less than 6 months.\n* Pregnant or lactating women.\n* Already participating in other clinical studies.","80 Years",{"count":53,"type":21},70,[55],"PHASE2","①Research objective: In a small sample population, through the pre - experimental method, explore and evaluate the effect of Guanxinning tablets on the coronary microcirculation after primary percutaneous coronary intervention (PPCI) in patients with acute ST - segment elevation myocardial infarction (STEMI), with the change in the percentage of intramyocardial hemorrhage (IMH) in ventricular mass measured by cardiac magnetic resonance (CMR) imaging as the primary endpoint.\n\n②Research significance: The research results of this project will provide preliminary theoretical basis and methodological support for the formal randomized controlled study on evaluating the effect of Guanxinning tablets on the coronary microcirculation after PPCI in STEMI patients. It will offer new ideas for the long - term clinical treatment of STEMI patients after PPCI, and provide important theoretical support for expanding the clinical indications of Guanxinning tablets and exploring the reasons for its improvement of cardiovascular outcomes.",[58,59,27,60,61],"STEMI (ST Elevation MI)","STEMI - ST Elevation Myocardial Infarction","CMD","Coronary Microvascular Dysfunction (CMD)",[63,64,65,66,67],"TCM","traditional chinese medicine","guanxinning tablet","CMR","intramyocardial hemorrhage","2026-05-27",{"date":70,"type":35},"2026-06-02",{"date":37,"type":21},{"date":73,"type":21},"2027-02-01",{"name":75,"class":42},"Beijing Anzhen Hospital",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":86,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":94,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":43},"100626499","drug-coated-balloon-primary-pci-in-st-segment-elevation-myocardial-infarction-100626499","NCT07436429","Drug-Coated Balloon Primary PCI in ST-Segment Elevation Myocardial Infarction","Drug Coated Balloon-Based Primary PCI in ST-segment Elevation Myocardial Infarction - The DCB-STEMI Multicenter Registry","DCB-STEMI","Inclusion Criteria:\n\n* All ST-elevation MI undergoing Primary PCI\n\nExclusion Criteria:\n\n* In-stent culprit lesion\n* Contraindications to antiplatelets\n* Stent implantation within 3 months before enrollment\n* Cardiac arrest, intubation, or cardiogenic shock\n* Life-expectancy less than one year",{"count":85,"type":21},300,"30 Days","OBSERVATIONAL","Drug-eluting stent (DES)-based primary percutaneous intervention (pPCI) has been established as the standard of care for patients presenting with ST-segment elevation myocardial infarction (STEMI), having demonstrated superiority over thrombolysis, plain balloon angioplasty, and bare-metal stents. Recently, the use of drug-coated balloons (DCB) has expanded dramatically across a variety of anatomical and clinical settings, including de novo coronary lesions. A DCB-based pPCI strategy may simplify the procedure and mitigate the risks of inadequate stent sizing due to spasm or large thrombus burden, acute stent thrombosis, distal embolization, no reflow, and the relatively higher incidence of late stent-related adverse events compared with elective PCI. Despite these theoretical advantages, data on the safety and efficacy of DCB-based pPCI in STEMI remains limited.\n\nThe aim of this registry is to explore procedural and clinical outcomes of patients with STEMI treated with a DCB-based pPCI strategy.",[90,91,27,92,93],"Myocardial Infarction (MI)","ST-Elevation Myocardial Infarction","STEMI (STE-ACS)","Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)",[95,96,97,98,99,100,101,102,103],"Drug-coated balloon","Primary percutaneous coronary intervention","De novo coronary lesion","Limus-coated balloon","Paclitaxel-coated balloon","Net adverse clinical events","Bleeding Academic Research Consortium bleeding","ST-segment elevation myocardial infarction","Drug-Eluting Balloon","RECRUITING","2026-02-22",{"date":107,"type":35},"2026-02-27",{"date":109,"type":35},"2026-02-08",{"date":111,"type":21},"2026-07-01",{"name":113,"class":42},"Medical University of Vienna",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":4},"100620162","the-coronary-sinus-balloon-pump-in-stemi-100620162","NCT07354035","The Coronary Sinus Balloon Pump in STEMI","A Prospective, Randomized, Multicenter Clinical Trial in Evaluating the Safety and Efficacy of the Use of Coronary Sinus Balloon Pump Along With PCI in STEMI Patients","REVIVE-RCT","Inclusion Criteria:\n\nGeneral Inclusion Criteria:\n\n1. Subjects aged ≥18 and ≤80 years, clinically diagnosed with ST-segment elevation myocardial infarction (STEMI).\n2. Left ventricular ejection fraction (LVEF) ≤50% and ≥35% as assessed by echocardiography or left ventriculography prior to PCI.\n3. Symptoms of myocardial infarction (e.g., persistent chest pain, with or without shortness of breath, nausea\u002Fvomiting, profuse sweating, dyspnea, syncope) consistent with the timing of myocardial ischemia, with symptom onset within 24 hours.\n4. Electrocardiographic evidence of acute anterior wall myocardial infarction, defined as ST-segment elevation ≥1 mm (0.1 mV) in at least two contiguous precordial leads on a 12-lead ECG. For leads V2 or V3, the following gender- and age-specific cutoffs apply:\n\n   * 2 mm (0.2 mV) in men ≥45 years old.\n   * 2.5 mm (0.25 mV) in men \\\u003C40 years old.\n   * 1.5 mm (0.15 mV) in women.\n5. Subject is eligible for primary percutaneous coronary intervention (primary PCI).\n6. Subject is able to understand the purpose of the study, voluntarily agrees to participate by signing the informed consent form acknowledging the risks and benefits described therein, and is willing and able to comply with the required clinical follow-up procedures.\n\nAngiographic Inclusion Criteria:\n\n1. The target lesion is located in the proximal or mid segment of the left anterior descending artery (LAD).\n2. TIMI flow grade of the target vessel is 0, 1, or 2 prior to PCI treatment.\n\nExclusion Criteria:\n\n1. Presence of an implant or foreign body within the coronary sinus.\n2. The target lesion involves the left main coronary artery, or there is a ≥50% stenosis in the left main coronary artery.\n3. Known allergy or contraindication to drugs or materials required during PCI and the use of the investigational device (including, but not limited to, sirolimus, dual antiplatelet therapy drugs, polyamide, polyurethane, polytetrafluoroethylene, or stainless steel).\n4. Presence of pericardial effusion (moderate or greater), cardiac tamponade, hemodynamically significant left\u002Fright shunt, or severe valvular heart disease.\n5. Intracardiac thrombus detected by echocardiography within 30 days prior to enrollment.\n6. History of acute myocardial infarction, or documented history of hospitalization for Q-wave infarction.\n7. History of cerebral infarction, intracerebral hemorrhage, transient ischemic attack (TIA), or reversible ischemic neurologic deficit within the past 6 months, or presence of permanent neurological deficit.\n8. Known hemoglobin level below 90 g\u002FL, platelet count below 80×10⁹\u002FL, history of bleeding diathesis or coagulation disorder, or unwillingness to receive blood transfusion.\n9. Subjects requiring circulatory support or assisted ventilation.\n10. Subjects experiencing cardiac arrest or cardiopulmonary resuscitation (CPR) for more than 5 minutes preoperatively (baseline) or intraoperatively.\n11. Subjects unsuitable for femoral or jugular venous access.\n12. Known contraindications to cardiac magnetic resonance imaging (CMR), such as claustrophobia, presence of non-CMR compatible foreign bodies or implants, or allergy\u002Fintolerance to gadolinium-based contrast agents.\n13. Prior coronary artery bypass graft (CABG) surgery.\n14. Visible well-developed collateral circulation distal to the target lesion in the target vessel.\n15. Current participation in another clinical drug or device study where the primary endpoint has not been reached, or planned participation in another investigational drug or device clinical trial within 12 months after the baseline procedure.\n16. Known severe renal disease (estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002F(min·1.73m²) as calculated by the MDRD formula\\*) or undergoing hemodialysis.\n17. History of treatment for malignancy within the past 12 months.\n18. Subjects with chronic obstructive pulmonary disease (COPD) who are on home oxygen therapy or receiving chronic steroid therapy.\n19. Impaired consciousness during PCI, cardiogenic shock (persistent systolic blood pressure ≤90 mmHg despite conservative treatment), or pulmonary edema (peripheral oxygen saturation \\\u003C90% with rales).\n20. Any vascular PCI treatment received within 1 week prior to enrollment.\n21. Fibrinolytic therapy received within 24 hours prior to enrollment.\n22. -target lesions in vessels other than the left anterior descending artery and its branches requiring treatment during this PCI or within one week thereafter.\n23. Known pregnancy or breastfeeding, or female subjects planning pregnancy within 1 year post-procedure and unable to complete follow-up as required.\n24. Subjects judged by the investigator to have poor compliance and unable to complete the study as required, or any other reason the investigator deems the subject unsuitable for enrollment.",{"count":123,"type":21},177,[24],"This study is a prospective, multicenter, randomized controlled clinical trial designed to evaluate the safety and efficacy of the coronary sinus balloon pump (manufactured by Shanghai MicroPort Rotapace Medical Technology Co., Ltd.) as an adjunctive therapy during percutaneous coronary intervention (PCI) in patients with acute ST-segment elevation myocardial infarction (STEMI). As a pivotal study, it aims to support the product registration application to the National Medical Products Administration (NMPA).",[27],"2026-01-20",{"date":129,"type":35},"2026-01-21",{"date":131,"type":21},"2026-02-12",{"date":133,"type":21},"2026-06",{"name":135,"class":136},"Shanghai MicroPort Rhythm MedTech Co., Ltd.","INDUSTRY",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":148,"conditions":149,"keywords":153,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":43},"100497961","phase-3-dapagliflozine-to-attenuate-cardiac-remodeling-after-acute-myocardial-infarction-100497961","NCT05764057","DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction","DAPAPROTECTOR","Inclusion Criteria:\n\n* Age ≥18 years;\n* STEMI (e.g., ST elevation above the J-point of ≥0.1 millivolt in ≥two contiguous leads or left bundle branch block) or very high-risk NSTEMI (e.g., dynamic ECG changes or ongoing chest pain or acute heart failure or hemodynamic instability independent of ECG changes or life-threatening ventricular arrhythmias) with LV dysfunction (LVEF ≤45%); after completion of PCI or angiography procedure\n* eGFR ≥ 25 mL\u002FMin per 1.73m²;\n* Systolic blood pressure (SBP) before first dosing \\>100 mmHg and\u002For Diastolic blood pressure (DBP) \\>70 mmHg before first dosing;\n* Ability to provide written informed consent and willing to participate in the 6-month follow-up period.\n* Affiliation to a national health care system (AME are not allowed).\n\nExclusion Criteria:\n\n* Cardiogenic shock (SBP \\\u003C90 mmHg with clinical signs of low output or patients requiring inotropic agents) at randomization;\n* Referred to surgery for coronary artery bypass grafting (CABG) or treatment of acute complications (e.g. ventricular septal rupture);\n* Any other form of diabetes than diabetes type 2\n* History of diabetic ketoacidosis (DKA); Known contra-indication to SGLT-2 inhibitors (hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption);\n* \\>1 episode of severe hypoglycemia within the last 6 months under treatment with insulin or sulfonylurea;\n* Acute symptomatic urinary tract infection (UTI) or genital infection at the time of randomization;\n* Concomitant treatment (and\u002For within the 4 weeks prior to the baseline visit) with any SGLT-2 inhibitor (dapagliflozin, canagliflozin, empagliflozin)\n* Echocardiographic examination of insufficient quality to permit adequate analysis of the study end-points.\n* Impossibility to evaluate cardiac remodeling using TTE (e.g., pacemaker or defibrillator …);\n* Atrial fibrillation rhythm at randomization;\n* Life expectancy \\\u003C6 month;\n* Known pregnancy at time of randomization;\n* Breastfeeding women\n* Females of childbearing potential without adequate contraceptive methods (i.e. sterilization, intrauterine device, vasectomized partner; or medical history of hysterectomy)\n* Current participation in another interventional trial. Patients under guardianship or curatorship",{"count":145,"type":21},450,[147],"PHASE3","Recent clinical trials have proven the cardiovascular benefits of new medications for patients with heart failure with reduced ejection fraction (HFrEF), especially sodium-glucose co-transporter 2 (SGLT2) inhibitors. There are no existing randomized clinical trials evaluating the efficacy and safety of dapagliflozin (nor any other SGLT2-inhibitor) to limit cardiac remodeling in patients with acute myocardial infarction (AMI) and left ventricular (LV) dysfunction.\n\nPreventing cardiac remodeling, an established predictor of subsequent heart failure (HF) and cardiovascular death, is likely to translate into benefit in reducing clinical events in post-MI patients.",[150,27,151,152],"AMI","NSTEMI","Left Ventricular Dysfunction",[154,155,156,157,158,159],"Acute myocardial infarction","Left ventricular dysfunction","Dapagliflozin","Transthoracic echocardiography","Cardiac remodeling","Cardiovascular Intensive Care Unit (CICU)","2025-12-12",{"date":162,"type":35},"2025-12-19",{"date":164,"type":35},"2023-06-12",{"date":166,"type":21},"2026-10-12",{"name":168,"class":42},"Assistance Publique - Hôpitaux de Paris",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":177,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":179,"conditions":180,"keywords":181,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":43},"100615532","impact-of-cardio-selective-beta-blockers-on-infarct-size-after-acute-myocardial-infarction-100615532","NCT07293832","Impact of Cardio-Selective Beta-Blockers on Infarct Size After Acute Myocardial Infarction","The Impact of Sympathetic Drive Control With Cardio-Selective Beta-Blockers on Infarct Size After Acute Myocardial Infarction","BLOCK-AMI","Inclusion Criteria:\n\n* Age between 18 and 80 years\n* Patients with electrocardiogram showing ST-segment elevation ≥2 mm in 2 or more contiguous leads for more than 30 minutes\n* Estimated time from symptom onset to reperfusion ≤12 hours\n* Patients scheduled to undergo primary angioplasty\n* Patients who have signed a consent form\n\nExclusion Criteria:\n\n* Patients receiving chronic medication with beta-adrenergic blockers\n* Patients with a previous myocardial infarction\n* Persistent systolic blood pressure \\\u003C90 mmHg\n* Persistent heart rate \\\u003C55 beats per minute\n* Patients with Killip class III (acute pulmonary edema) or IV (cardiogenic shock) on initial examination\n* 12-lead electrocardiogram with PR interval \\>200 milliseconds\n* 12-lead electrocardiogram showing second- or third-degree atrioventricular block\n* Bronchospasm requiring bronchodilator treatment\n* Possible pregnancy or postpartum period\n* Inability or refusal to sign the consent form",{"count":178,"type":21},100,"Introduction: The effect of intravenous beta-blockers on the extent of the necrotic area, after primary percutaneous transluminal coronary angioplasty (PTCA), for acute myocardial infarction is not well established.\n\nPurpose: The present study aims to investigate, whether the early intravenous administration of landiolol, a highly cardioselective b-blocker, reduces the extent of the necrotic area after ST-elevation myocardial infarction (STEMI).\n\nMethods: This prospective observational cohort study will enroll patients presenting with STEMI, who undergo primary PCI and receive either intravenous landiolol or standard oral β-blocker therapy, in accordance with current European Society of Cardiology (ESC) guidelines. Eligibility will be determined by predefined inclusion and exclusion criteria. Treatment selection will be based solely on the clinical judgment of the attending cardiologist, without randomization.\n\nResults: Final infarct size will be quantified by cardiac magnetic resonance imaging (CMR) performed at least three months after the STEMI to minimize edema-related overestimation. Myocardial function will be assessed during hospitalization using transthoracic echocardiography, including measurement of global longitudinal strain (GLS). Additional data will include serial high-sensitivity troponin and creatine phosphokinase (CPK) measurements, 24-hour continuous electrocardiographic monitoring for arrhythmia burden, and predefined safety outcomes collected throughout hospitalization.",[27],[182],"beta-blocker","2025-12-07",{"date":162,"type":35},{"date":186,"type":35},"2024-11-13",{"date":188,"type":21},"2026-08",{"name":190,"class":42},"Aristotle University Of Thessaloniki",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":199,"enrollmentInfo":200,"targetDuration":202,"studyType":87,"phases":4,"briefSummary":203,"conditions":204,"keywords":209,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":43},"100594996","tirana-acs-a-prospective-registry-study-for-the-targeted-investigation-of-residual-inflammation-after-non-st-st-elevation-acute-coronary-syndrome-100594996","NCT07026708","TIRANA-ACS: A Prospective Registry Study for the Targeted Investigation of Residual Inflammation After Non-ST\u002F ST Elevation Acute Coronary Syndrome","Target Investigation of Residual Inflammation After Non-ST\u002F ST Elevation Acute Coronary Syndrome - TIRANA (ACS) Prospective REGISTRY","TIRANA (ACS)","Inclusion Criteria:\n\n\\- All patients (undergoing PCI, aged 18-85 years) presenting to the cardiology department or\u002Fand the cardiology intensive care unit with a diagnosis of ACS\n\nExclusion Criteria:\n\n* Patients presenting to the cardiology department or\u002Fand the cardiology intensive care unit with diagnoses other than ACS and\u002For UA. Patients who died before undergoing PCI and those who did not provide a contact number.","85 Years",{"count":201,"type":21},1600,"2 Years","This prospective observational study aims to evaluate the prognostic significance of the neutrophil-to-lymphocyte ratio (NLR) as a predictor of mortality in patients following an episode of Acute Coronary Syndrome (ACS). Despite advancements in interventional cardiology and medical therapy, mortality remains significant in post-ACS patients, and early risk stratification is essential for optimizing outcomes.\n\nRecent studies have suggested that systemic inflammatory markers, such as NLR, are associated with adverse cardiovascular events. It is an easily obtainable and cost-effective laboratory parameter derived from a routine complete blood count. However, its value as an independent predictor of mortality post-ACS has not yet been fully established in our population.\n\nThe study will include patients aged, admitted with a confirmed diagnosis of ACS (STEMI or Non-STEMI) and treated with percutaneous coronary intervention (PCI). NLR values will be measured from the first blood draw upon hospital admission, 24 and 48 hours post PCI. Patients will be followed up for up to 6 months after discharge through telephone interviews .\n\nFirst, primary outcomes of the study will be the association between NLR values and mortality (all cause mortality and cardiovascular mortality), MACE (MACE was defined as the composite of all-cause mortality, cardiac death, unplanned revascularization, non-fatal myocardial infarction that was attributable and not related to stent failure or unplanned revascularization not related to stent failure) within 6 months post-ACS.\n\nSecondary outcomes will include:\n\n1. Differences in mean NLR between STEMI and NSTEMI patients.\n2. Association between elevated NLR and the presence of multivessel coronary artery disease on angiography.\n3. Correlation of NLR with other biomarkers, including the platelet-to-lymphocyte ratio (PLR), C-reactive protein (CRP), high-density lipoprotein (HDL) cholesterol, and maximum troponin levels (as an indicator of myocardial infarction size)\n\nThis study aims to contribute to the identification of easily accessible and cost-efficient biomarkers that can aid clinicians in early risk stratification of ACS survivors. A strong correlation between high NLR values and increased post-discharge mortality would suggest that inflammation plays a key role in patient prognosis and could potentially influence post-ACS management strategies.",[205,90,206,207,208,27],"ACS (Acute Coronary Syndrome)","Myocardial Inflammation","Inflammation Biomarkers","NSTEMI - Non-ST Segment Elevation MI",[210,211,212,213],"Residual inflammation","Myocardial infarction","Percutaneous Coronary Intervention","Acute Coronary Syndrome","2025-09-27",{"date":216,"type":35},"2025-09-30",{"date":218,"type":35},"2024-11-01",{"date":220,"type":21},"2027-06-01",{"name":222,"class":42},"University Hospital Centre Mother Teresa",{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":230,"targetDuration":232,"studyType":87,"phases":4,"briefSummary":233,"conditions":234,"keywords":236,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":4},"100604890","inflammatory-and-hematological-indices-in-diabetic-stemi-patients-undergoing-primary-pci-100604890","NCT07155395","Inflammatory and Hematological Indices in Diabetic STEMI Patients Undergoing Primary PCI","Relationship Between Inflammatory and Hematological Indices and Coronary Artery Disease Severity and Outcome Among Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention","Inclusion Criteria:\n\n* Patients presenting to Assiut University cardiac catheterization laboratory with ST-segment Elevation Myocardial Infarction (STEMI).\n* Managed with primary percutaneous coronary intervention (PPCI).\n\nExclusion Criteria:\n\n* Patients not eligible for PPCI.\n* Patients who underwent thrombolytic therapy or received anti-thrombotics prior to hospital arrival.\n* Prior coronary intervention: history of PCI or CABG.\n* Known hematological disorders:\n\nThalassemia (microcytic anemia, normal iron profile, HbA2 ≥ 3.5% or elevated HbF).\n\nMyelodysplastic syndromes (unexplained cytopenias with ≥10% dysplasia in bone marrow aspirate).\n\nLeukemia (persistent leukocytosis or pancytopenia, blasts ≥20% in peripheral blood).\n\n* Active infection or sepsis at admission (e.g., fever, leukocytosis, elevated CRP \\\u003C100 mg\u002FL without cardiac cause).\n* Known autoimmune or chronic inflammatory diseases (e.g., systemic lupus erythematosus).\n* Known or newly diagnosed malignancy.\n* End-stage renal disease (eGFR \\\u003C30 ml\u002Fmin\u002F1.73 m² or on dialysis).\n* Advanced hepatic impairment (Child-Pugh class C; bilirubin \\>3 mg\u002FdL or ALT\u002FAST \\>3× upper limit of normal).\n* Recent blood transfusion within 3 months.\n* Recent use of steroids, chemotherapy, or immunosuppressive drugs.\n* Mechanical complications or cardiogenic shock prior to or during STEMI presentation (e.g., papillary muscle rupture, ventricular septal defect, need for intra-aortic balloon pump).",{"count":231,"type":21},1000,"6 Months","ST-segment Elevation Myocardial Infarction (STEMI) remains a major cause of mortality despite the adoption of Primary Percutaneous Coronary Intervention (PPCI) as the standard treatment. However, outcomes still vary significantly among patients, especially between diabetic and non-diabetic cohorts.\n\nThe research question driving this study is: Can hematologic, inflammatory, and thrombotic indices serve as reliable prognostic tools in predicting the no-reflow phenomenon and coronary artery disease (CAD) severity in STEMI patients, particularly among those with diabetes mellitus?\n\nRecent literature identifies inflammation as a key contributor to the pathogenesis and outcomes of Acute Coronary Syndrome (ACS), including the no-reflow phenomenon and Major Adverse Cardiovascular Events (MACE). Markers such as C-reactive protein (CRP), Neutrophil-to-Albumin Ratio (NAR), Red Cell Distribution Width (RDW), Platelet Distribution Width (PDW), Hemoglobin-to-Red Cell Distribution Width ratio (Hb\u002FRDW), and the RDW\u002FPDW ratio have shown individual correlations with poor outcomes. Emerging indices such as the Systemic Immune-Inflammation Index (SII) and the Systemic Inflammatory Response Index (SIRI) further integrate immune and inflammatory components and have shown promise in early risk stratification.\n\nThe current strategy in many cardiac centers relies on angiographic and clinical indicators, which may be insufficient for individualized risk prediction. Hence, incorporating accessible and cost-effective blood-based markers could significantly enhance prognostic accuracy.\n\nThe rationale of this research lies in comparing these indices in diabetic versus non-diabetic STEMI patients, aiming to stratify risk, predict no-reflow, assess coronary artery disease burden using the SYNTAX score, and identify those at risk for early adverse outcomes.",[27,235],"Diabete Mellitus",[27,237,238,239,240,241,242,243,244,245,246],"Diabetes","No reflow","SYNTAX","Hb\u002FRDW","RDW\u002FPDW","NAR","SIRI","SII","CRP","PPCI","2025-09-01",{"date":249,"type":35},"2025-09-04",{"date":251,"type":21},"2025-10",{"date":253,"type":21},"2027-04",{"name":255,"class":42},"Assiut University",{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":264,"targetDuration":4,"studyType":22,"phases":266,"briefSummary":267,"conditions":268,"keywords":269,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":4},"100599258","the-first-in-man-use-of-coronary-sinus-balloon-pump-in-stemi-patients-treated-by-primary-pci-100599258","NCT07082153","The First-In-Man Use of Coronary Sinus Balloon Pump in STEMI Patients Treated by Primary PCI","A Prospective, Multicenter Clinical trIal in Evaluating the Safety and Efficacy of the Coronary Sinus Balloon Pump for the First-In-Man Use in STEMI Patients","REVIVE-FIM","Inclusion Criteria:\n\nClinical inclusion criteria：\n\n1. Subjects aged ≥18 and ≤80 years with clinically confirmed ST-segment elevation myocardial infarction (STEMI).\n2. Left Ventricular Dysfunction: Left ventricular ejection fraction (LVEF) ≤50% assessed by pre-PCI echocardiography or left ventriculography.\n3. Ischemic Symptoms: Presence of myocardial infarction symptoms consistent with ischemic timing (e.g., persistent chest pain, with or without dyspnea, nausea\u002Fvomiting, diaphoresis, syncope), with symptom onset between 6 and 24 hours prior to enrollment.\n4. Electrocardiographic Evidence:\n\n   * Acute anterior wall myocardial infarction confirmed by 12-lead ECG, demonstrating ST-segment elevation ≥1 mm (0.1 mV) in ≥2 contiguous precordial leads.\n   * For leads V2 or V3:\n\n   Men: ST-segment elevation ≥2 mm (0.2 mV) Women: ST-segment elevation ≥1.5 mm (0.15 mV).\n5. PCI Eligibility: Candidate for primary percutaneous coronary intervention (PCI).\n6. Subjects who can understand the purpose of the trial, voluntarily participate and acknowledge the risks and benefits described in the informed consent document by signing the informed consent form, and can conscientiously complete clinical follow-up as required\n\nAngiography Inclusion Criteria:\n\n1. Target Lesion Location: Located in the proximal or mid segment of the Left Anterior Descending artery (LAD).\n2. Pre-PCI TIMI Flow: TIMI flow grade 0 or 1 in the target vessel prior to percutaneous coronary intervention (PCI).\n\nExclusion Criteria:\n\n1. Presence of implants or foreign bodies within the coronary sinus.\n2. Target lesion involving the left main coronary artery or ≥50% stenosis in the left main coronary artery.\n3. Known hypersensitivity to medications or devices required during PCI or the investigational device (including but not limited to: rapamycin, polyurethane in dual antiplatelet therapy, PET, or stainless steel).\n4. Pericardial effusion (moderate or larger volume), cardiac tamponade, hemodynamically significant left\u002Fright shunts, or severe valvular heart disease.\n5. Intracardiac thrombus detected by echocardiography within 30 days prior to enrollment.\n6. History of acute myocardial infarction (AMI) or documented hospitalization for Q-wave infarction.\n7. History of cerebral infarction, intracranial hemorrhage, transient ischemic attack (TIA), or reversible ischemic neurologic deficit within the past 6 months, or permanent neurological deficits.\n8. Hemoglobin \\\u003C90 g\u002FL, platelet count \\\u003C80×10⁹\u002FL, history of bleeding disorders\u002Fcoagulopathy, or refusal to accept blood transfusion.\n9. Requiring circulatory support or assisted ventilation therapy.\n10. Cardiac arrest or cardiopulmonary resuscitation (CPR) \\>5 minutes during pre-procedural baseline or intra-procedural period.\n11. Unsuitable femoral or jugular venous access.\n12. Contraindications to cardiac magnetic resonance imaging (CMR), including claustrophobia, CMR-incompatible implants\u002Fforeign bodies, or gadolinium contrast allergy\u002Fintolerance.\n13. Prior coronary artery bypass grafting (CABG).\n14. Visible collateral circulation formation distal to the target lesion in the target vessel.\n15. Current participation in another investigational drug\u002Fdevice trial (prior to primary endpoint completion) or planned enrollment in another trial within 12 months post-procedure.\n16. Severe renal dysfunction (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m² by MDRD equation\\*) or ongoing hemodialysis.\n17. Active malignancy treatment within the past 12 months.\n18. Chronic obstructive pulmonary disease (COPD) requiring home oxygen therapy or chronic steroid therapy.\n19. Impaired consciousness during PCI, cardiogenic shock (persistent SBP ≤90 mmHg despite conservative therapy), or pulmonary edema (peripheral SpO₂ \\\u003C90% with rales).\n20. Any vascular PCI performed within 7 days prior to hospitalization.\n21. Fibrinolytic therapy administered within 24 hours prior to hospitalization.\n22. Non-target lesions requiring treatment during index PCI or within 1 week post-procedure (excluding LAD and its branches).\n23. Pregnancy, lactation, or female subjects planning pregnancy within 1 year post-procedure unable to complete follow-up.\n24. Poor protocol compliance per investigator's judgment, or subjects deemed ineligible due to other reasons.",{"count":265,"type":21},10,[24],"This is a prospective, multicenter clinical investigation aiming to evaluate the safety and efficacy of the coronary sinus balloon pump in its first application in patients with acute ST-segment elevation myocardial infarction (STEMI).",[27],[27,270],"the coronary sinus balloon pump","2025-07-21",{"date":273,"type":35},"2025-07-24",{"date":275,"type":21},"2025-08-12",{"date":277,"type":21},"2026-03-03",{"name":135,"class":136},{"id":280,"slug":281,"hasResults":11,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":287,"targetDuration":289,"studyType":87,"phases":4,"briefSummary":290,"conditions":291,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":43},"100596160","remodeling-in-st-elevation-myocarrdial-infarction-a-comparison-of-left-ventricular-functions-in-long-term-follow-up-among-stemi-patients-100596160","NCT07041840","ReModeling in ST-elevation myocARrdial Infarction: a Comparison of Left VEntricuLar Functions in Long-term Follow-up Among STEMI Patients","ReModeling in ST-elevation myocARrdial Infarction: a Comparison of Left VEntricuLar Functions in Long-term Follow-up Among STEMI Patients: The MARVEL Study","MARVEL","Inclusion Criteria:\n\n* STEMI\n\nExclusion Criteria:\n\n* Contraindication to CMR imaging",{"count":288,"type":21},80,"36 Months","Patients diagnosed with STEMI who underwent pPCI were included in this study. The investigators collected comprehensive data on each patient's status, including laboratory findings such as NT-proBNP, troponin levels, and inflammatory profile assessed by leukocyte count, C-reactive protein, interleukin-1, and interleukin-6. Additionally, electrocardiographic and echocardiographic features, details of the coronary intervention procedure, hospital stay duration, complications, and medical treatments were recorded.\n\nComprehensive transthoracic echocardiograms (TTE) were performed at admission and before discharge. Myocardial tissue characterization was conducted by cardiac magnetic resonance (CMR) imaging before discharge, assessing intramyocardial hemorrhage (IMH), microvascular obstruction (MVO), infarct size (IS), area at risk (AAR), salvaged myocardium, and salvage index.\n\nAt the six-month follow-up, laboratory tests, CMR imaging, and TTE were repeated, along with a thorough clinical evaluation. LVR was defined by one of the following criteria: a 20% increase in end-diastolic volume by TTE or 12% by CMR, a 15% increase in end-systolic volume, a sphericity index greater than 42% (CMR only), the emergence of new concentric hypertrophy, or a reduction greater than 10% in left ventricular ejection fraction (LVEF).",[27],"2025-07-13",{"date":294,"type":35},"2025-07-17",{"date":296,"type":35},"2024-01-01",{"date":298,"type":21},"2027-01-01",{"name":300,"class":42},"University of Pisa",{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":308,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":309,"targetDuration":311,"studyType":87,"phases":4,"briefSummary":312,"conditions":313,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":322,"locationsCount":43},"100597181","retinal-octa-for-microvascular-dysfunction-evaluation-and-outcome-prediction-in-minoca-patients-100597181","NCT07055152","Retinal OCTA for Microvascular Dysfunction Evaluation and Outcome Prediction in MINOCA Patients","REVEAL","Inclusion Criteria:\n\n* Age: Patients aged \\> 18.\n\nDiagnosis:\n\nMINOCA Group: Patients diagnosed with Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA) confirmed by coronary angiography.\n\nACS Group: Patients with Acute Coronary Syndrome (ACS) with significant coronary artery stenosis which are matched with MINOCA patients for gender, age, LVEF at admission and chronic kidney disease stage.\n\nHealthy Controls: Age and gender-matched healthy individuals with no history of cardiovascular disease.\n\nConsent: Written informed consent obtained from all participants. Feasibility: Ability to undergo OCTA and other required imaging procedures.\n\nExclusion Criteria:\n\n* Ocular Conditions: Any significant ocular disease (e.g., glaucoma, diabetic retinopathy, macular degeneration) that could interfere with OCTA imaging quality.\n\nSevere Comorbidities: Presence of severe systemic diseases, such as advanced renal failure, active cancer, or severe liver disease, which might impact study participation.\n\nCoronary Artery Disease or Myocarditis: For the MINOCA group, patients with coronary artery stenosis \\> 50% or functionally significant (FFR \\\u003C0.8) or patients with Myocarditis detected through CMR will be excluded Pregnancy: Pregnant or breastfeeding women. Inability to Comply: Patients unable or unwilling to comply with study procedures, including follow-up visits.",true,{"count":310,"type":21},90,"24 Months","The aim of this study is to evaluate microvascular dysfunction through OCTA in MINOCA patients. In order to better understand the condition, OCTA will also be performed in two matched patient groups: healthy controls and ACS patients. The study will compare the retinal microvascular parameters across these groups to determine differences in microvascular function in MINOCA patients. Additionally, in the MINOCA subgroup, the study will further evaluate the differences in microvascular dysfunction within specific subsets of patients (e.g., Takotsubo, vasospastic angina, microvascular angina, patients with evidence of plaque erosion) to understand the variability and potential mechanisms underlying each subgroup of MINOCA.",[314,27,315],"MINOCA","Normal","2025-07-03",{"date":318,"type":35},"2025-07-08",{"date":320,"type":35},"2025-01-01",{"date":298,"type":21},{"name":300,"class":42},{"id":324,"slug":325,"hasResults":11,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":22,"phases":332,"briefSummary":333,"conditions":334,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":342,"leadSponsor":344,"locationsCount":43},"100590381","no-reflow-in-patients-with-stemi-after-intracoronary-tirofiban-after-opening-of-the-track-100590381","NCT06966674","No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track","Assessment of No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track","Inclusion Criteria:\n\n* Age ≥ 18 years old.\n* Both sexes.\n* Patients with STEMI. ST-segment elevated myocardial infarction is defined as typical chest pain \\>30 minutes with ST-segment elevation of \\>1 mm in at least 2 consecutive leads on the electrocardiogram or new-onset left bundle brunch block.\n\nExclusion Criteria:\n\n* Treatment with thrombolytic drugs in the previous 24 hours.\n* Known malignancy.\n* Thrombocytopenia.\n* End-stage liver disease.\n* Cardiogenic shock.\n* Renal failure with glomerular filtration\\\u003C30 ml\u002Fmin.\n* Contraindication for the use of tirofiban.",{"count":331,"type":21},60,[24],"This study aims to assess the no-reflow in patients with STEMI after intracoronary glycoprotein IIb\u002FIIIa inhibitors after opening of track in thrombus.",[335,27,336,337],"No-Reflow","Intracoronary","Tirofiban","2025-05-12",{"date":340,"type":35},"2025-05-13",{"date":338,"type":35},{"date":343,"type":21},"2025-10-01",{"name":345,"class":42},"Kafrelsheikh University",{"id":347,"slug":348,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":352,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":22,"phases":356,"briefSummary":357,"conditions":358,"keywords":361,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":376},"100424919","remote-ischaemic-conditioning-in-stemi-patients-in-africa-100424919","NCT04813159","Remote Ischaemic Conditioning in STEMI Patients in AFRICA","Remote Ischaemic Conditioning in STEMI Patients in AFRICA: The RIC-AFRICA Trial","RIC-AFRICA","We will be recruiting 3 different strata of STEMI patients.\n\n1. Adult patients (≥18 years old) presenting with STEMI receiving thrombolytic therapy within guideline-recommended time (i.e., within \\\u003C12 hours of most severe chest pain onset).\n2. Adult patients (≥18 years old) presenting with STEMI who are ineligible for thrombolysis because they present outside of guideline-recommended time (\\\u003C12 hours) but within 24 hours of most severe chest pain onset.\n3. Adult patients (≥18 years old) presenting with evidence of STEMI who do not receive thrombolysis and who present ≥24 hours and within 72 hours of most severe chest pain onset.\n\nInterventional arm of the Study: Randomized Control Trial\n\nPatients who are deemed eligible for randomization into the trial on account of presentation with STEMI within 24 hours, will be eligible for the interventional arm of the study if the following inclusion\u002Fexclusion criteria are met.\n\nInclusion Criteria\n\nI. Adult patients (≥18 years old) presenting with suspected STEMI (ST-elevation at the J-point in two contiguous leads ( ≥ 0.2mV in men or ≥ 0.15mV in women in leads V2-V3 and\u002For ≥ 0.1mV in other lead); and II. Within 24 hours of onset of myocardial infarction as deemed by the attending clinician; and III. Signed informed consent.\n\nExclusion criteria\n\nI. STEMI patients due to undergo primary percutaneous coronary intervention;\n\nII. STEMI patients presenting with cardiogenic shock or haemodynamic instability as defined by: systolic blood pressure (SBP) measurement of \\\u003C90 mm Hg for ≥30 minutes; or use of pharmacological and\u002For mechanical support to maintain SBP ≥ 90 mm Hg; and evidence of end-organ damage defined by: urine output of \\\u003C30 mL\u002Fh; altered mental status; and\u002For serum lactate \\>2.0 mmol\u002FL;\n\nIII. Contraindications for the use of RIC or sham-control on either arm such as:\n\n1. severe active skin disease\u002Fburns on both arms; or\n2. bilateral upper limb amputations; or\n3. evidence of acute limb ischaemia on either arm; or\n4. active upper limb gangrene of any digits;\n5. breast cancer with lymph-node involvement on the ipsilateral side of RIC; or\n6. bilateral arteriovenous fistulae needed for haemodialysis.\n\nIV. Inter-current disease with an expected life expectancy of less than 24 hours;\n\nV. Contra-indication to thrombolytic therapy in patients presenting within guideline-recommended time (\\\u003C12 hours).\n\nObservational arm of the study\n\nPatients who are deemed ineligible for randomization into the trial on account of presentation beyond 24 hours, will be eligible for the observational arm of the study if the following inclusion\u002Fexclusion criteria are met.\n\nInclusion Criteria\n\nI. Signed informed consent; and\n\nII. Clinical evidence of STEMI older than 24 hours and less than 72 hours as defined by:\n\n1. Compatible history with maximal chest pain between 24 -72 hours prior to presentation; and\n2. Compatible biomarkers (elevated cardiac troponin); and\n3. ECG compatible with recent STEMI; and\u002For\n4. Compatible echocardiography.\n\nExclusion criteria\n\nI. Refusal or inability to sign informed consent.",{"count":355,"type":21},1400,[24],"The RIC-AFRICA trial is a multi-centre, sham-controlled, randomised controlled trial (RCT) involving 1400 ST-segment elevation myocardial infarction (STEMI) patients presenting within ≤ 24 hours of myocardial infarction (MI) onset, across approximately 25 sites in 7 African countries (South Africa, Kenya, Sudan, Uganda, Mozambique, Senegal and Mauritius). Patients presenting with STEMI and deemed ineligible for the RIC AFRICA RCT because they present \\>24 hours from MI onset but less than 72 hours, will be recruited into the observational arm of the study with the same endpoints as the trial. The purpose of the RCT is to determine whether Remote Ischaemic Conditioning (RIC) can reduce the rates of all-cause death and early post-myocardial heart failure at 30-days in STEMI patients treated predominantly with thrombolytic therapy.",[27,359,360],"Remote Ischaemic Conditioning","Myocardial Reperfusion Injury",[362,363,364,365,359,366,27],"Cardioprotection","Ischaemia\u002Freperfusion injury","ST-Elevation myocardial infarction","Hospitalisation for post-myocardial infarction heart failure","Cardiovascular mortality","2025-03-31",{"date":369,"type":35},"2025-04-03",{"date":371,"type":35},"2022-01-12",{"date":373,"type":21},"2027-12-31",{"name":375,"class":42},"University of Cape Town",20,{"id":378,"slug":379,"hasResults":11,"nctId":380,"briefTitle":381,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":383,"enrollmentInfo":384,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":386,"conditions":387,"keywords":390,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":4},"100574322","evaluation-of-remnant-cholesterol-levels-and-monocyte-to-hdl-cholesterol-ratio-as-predictors-of-coronary-artery-disease-severity-in-patients-with-acute-coronary-syndrome-100574322","NCT06757777","Evaluation of Remnant Cholesterol Levels and Monocyte-to-HDL-cholesterol Ratio as Predictors of Coronary Artery Disease Severity in Patients With Acute Coronary Syndrome","Inclusion Criteria:\n\n* Patients with acute coronary syndrome presented to ER of Assiut university hospital scheduled for primary PCI and able to provide informed consent.\n\nExclusion Criteria:\n\n* Patients on previous statin therapy.\n* Patients with severe renal dysfunction (creatinine clearance \\\u003C30 mL\u002Fmin) or other contraindications to PCI.\n* Patients with missed data or who couldn't be followed up","65 Years",{"count":385,"type":21},54,"1. Evaluation of serum level of remnant cholesterol and monocyte\u002FHDL ratio as predictors of severity of coronary artery disease in patients with acute coronary syndrome.\n2. Evaluate predictive value of remnant cholesterol serum level and monocyte\u002FHDL ratio to detect in-hospital worse clinical outcomes and 45 days major adverse cardiac events (MACE) after acute coronary syndrome.",[213,205,388,27,389],"Monocyte to HDL Cholesterol Ratio","Non STEMI",[391,392,27,393,394],"Acs","Acute coronary syndrome","NON STEMI","Monocyte\u002FHDL Ratio","2025-02-07",{"date":397,"type":35},"2025-02-11",{"date":399,"type":21},"2025-02-08",{"date":401,"type":21},"2026-03-08",{"name":255,"class":42},{"id":404,"slug":405,"hasResults":11,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":4,"eligibilityCriteria":409,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":410,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":412,"conditions":413,"keywords":415,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":4},"100573749","outcomes-of-isolated-lcx-occlusion-100573749","NCT06750328","Outcomes of Isolated LCx Occlusion","Procedural and Clinical Outcomes of Isolated Left Circumflex Coronary Artery Acute Occlusion in Patients Undergoing Primary Percutaneous Coronary Intervention","Inclusion Criteria:\n\n* Patients presented to Assiut University heart hospital with STEMI who underwent primary PCI that revealed isolated LCx acute occlusion (single culprit artery) between January 2018 to January 2025 will be included.\n\nExclusion Criteria:\n\n-Patients with cardiogenic shock, NYHA class III-IV and multivessel coronary artery disease will be excluded.",{"count":411,"type":21},50,"To assess procedural success and short term clinical outcomes of primary PCI to isolated LCx acute occlusion.",[414,27],"LCx Occlusion STEMI",[416],"LCx occlusion STEMI","2024-12-24",{"date":419,"type":35},"2024-12-27",{"date":421,"type":21},"2024-12-16",{"date":423,"type":21},"2027-11-12",{"name":255,"class":42},{"id":426,"slug":427,"hasResults":11,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":431,"eligibilityCriteria":432,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":22,"phases":435,"briefSummary":436,"conditions":437,"keywords":439,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":457},"100362371","phase-3-a-study-of-low-dose-intracoronary-thrombolytic-therapy-in-stemi-heart-attack-patients-100362371","NCT03998319","A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients.","A Randomised Trial to Evaluate the Efficacy of Low-dose Intracoronary Tenecteplase in ST-Elevation Myocardial Infarction (STEMI) Patients With High Microvascular Resistance Post-percutaneous Coronary Intervention (PCI).","RESTORE-MI","Inclusion Criteria:\n\n1. Adult men and women aged over 18 who present with STEMI within 6 hours of symptom onset. Patients will be eligible if they have symptoms consistent with myocardial ischaemia (chest pain, dyspnoea) for at least 20 minutes accompanied by definite ECGs indicating STEMI as defined by Australian National Heart Foundation (NHF) guidelines\n2. Willing and able to comply with all study requirements, including treatment, assessment and clinic visit attendances\n3. Able to personally read and understand the Participant Information and Consent Form and provide written, signed and dated informed consent to participate in the study\n4. (At time of PCI) Patient has received metallic drug-eluting stent\n5. Participant consents to have a 3-7 day (discharge) and 6 month follow up cardiac MRI\n\nExclusion Criteria:\n\nAt the time of screening and\u002For prior to randomisation, no known;\n\n1. Previous coronary bypass grafting\n2. Other residual lesions with ≥50% diameter stenosis in the culprit vessel\n3. Prior myocardial infarction in the target territory\n4. Presence of contraindications to thrombolytic therapy (including history of stroke and recent brain surgery active internal bleeding; history of cerebrovascular accident; intracranial or intraspinal surgery, or trauma within 2 months; intracranial neoplasm, arteriovenous malformation, or aneurysm; known bleeding diathesis; and severe uncontrolled hypertension)\n5. Presence of contraindications to adenosine infusion for IMR measurement including sinus node disease, moderate to severe bronchoconstrictive disease and second or third-degree atrioventricular (AV) block\n6. Diagnosis of metastatic disease\n7. Concurrent illness, including severe infection that may jeopardise the ability of the patient to undergo the procedures outlined in this protocol with reasonable safety\n8. Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol\n9. Pregnancy, lactation, or inadequate contraception. Women must be post-menopausal, infertile, or use a reliable means of contraception. Women of childbearing potential must have a negative pregnancy test done within 7 days prior to registration. Men must have been surgically sterilised or use a (double if required) barrier method of contraception.\n10. Participation in any investigational study in the previous 30 days\n\n    Other exclusion criteria:\n11. (Cardiac MRI cohort only) Presence of contraindications to contrast enhanced MRI including severe claustrophobia, pregnancy, pacemakers, non-MRI compatible aneurysm clips, defibrillators and estimated glomerular filtration rate of \\<30mL\u002Fmin.\n\n    (At time of PCI)\n12. Patients who received GpIIb\u002FIIIa treatment prior to IMR measurement\n13. Patients who do not undergo primary PCI due to lack of severity of culprit lesion or other reasons.",{"count":434,"type":21},445,[147],"Heart attacks are caused by a blood clot blocking the blood vessels of the heart, preventing blood getting to the heart muscle. Opening up the artery with a balloon (angioplasty) and a small mesh tube (stent) although life saving can cause this clot to break up and get washed downstream, which can make the heart attack worse. The investigators can measure the amount of damage caused to the microcirculation by calculating the IMR (Index of Microcirculatory resistance).\n\nThis can be measured by a wire in the coronary artery with a pressure sensor at the tip. If the IMR is elevated, it is suggestive of extensive microcirculatory damage. A clot dissolving medicine can be administered in the artery to try and reduce the IMR which can reduce damage to the heart muscle and improve outcomes.\n\nImpaired microcirculatory perfusion in patients as a result of ST-elevation myocardial infarction (STEMI) is associated with poor clinical outcomes. This project seeks to identify patients with impaired microcirculatory perfusion after STEMI and to assess whether acute improvement in microcirculatory perfusion in these patients by the use of intracoronary thrombolytic therapy results in improved clinical outcomes.",[27,438],"Elevated IMR (>32)",[27,440,441,442,443,444,445,28,446,447],"IMR","microcirculation","microvascular obstruction","myocardial infarction","physiology","angioplasty","thrombolysis treatment","thrombolysis","2024-09-25",{"date":450,"type":35},"2024-09-27",{"date":452,"type":35},"2021-10-14",{"date":454,"type":21},"2026-12-31",{"name":456,"class":42},"University of Sydney",22,{"id":459,"slug":460,"hasResults":11,"nctId":461,"briefTitle":462,"officialTitle":463,"acronym":4,"eligibilityCriteria":464,"healthyVolunteers":308,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":465,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":466,"conditions":467,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":43},"100553867","nlr-and-crp-useful-as-cost-effective-preliminary-prognostic-markers-in-st-elevation-myocardial-infarction-100553867","NCT06491667","NLR AND CRP Useful as Cost-Effective Preliminary Prognostic Markers in ST-Elevation Myocardial Infarction","Neutrophil-to-Lymphocyte Ratio AND C-REATIVE PROTEIN Useful as Cost-Effective Preliminary Prognostic Markers in ST-Elevation Myocardial Infarction","Inclusion Criteria:\n\n* Patients with age ≥18 years of either sex, with either increase in serum cardiac biomarkers or ECG are STEMI.\n\nExclusion Criteria:\n\n* Patients presenting with NSTEMI and unstable angina\n* Patients with any of these associated conditions that can affect NLR or CRP including\n* Inflammatory conditions such as collagen-vascular disorders\n* Acute or chronic infectious diseases.\n* Auto-immune and neoplastic diseases.\n* Chronic hepatic diseases.\n* Renal failure.\n* Thyroid disorders.\n* Previous valvular heart disease.",{"count":178,"type":21},"Acute myocardial infarction (AMI) is a serious and fatal cardiovascular emergency and considered the leading cause of mortality worldwide.\n\nAtherosclerosis of coronary arteries which takes decades to manifest clinically, is the primary predisposing pathologic factor responsible for the development of coronary heart disease It has been shown that A complex immune and inflammatory pathophysiological process is thought to be crucial for in the initiation and progression of atherosclerotic plaques.\n\nInflammation is one of the main mechanisms in the pathogenesis of atherosclerosis , Destabilization of chronic artery plaques and development of thrombosis, which are the main mechanisms in the pathophysiology of ST-segment elevation myocardial infarction (STEMI).\n\n, and the interest to the evaluation of inflammatory biomarkers in coronary artery disease (CAD) has been increasing over the last decade .\n\nAlthough numerous inflammatory markers, including troponin T\u002FI, lactate dehydrogenase (LDH), and creatine kinase (CK-MB), are linked to worsened clinical outcomes in both ST elevation and non-ST elevation myocardial infarction (NSTEMI), there is an unmet need for a cost-effective biomarker for impoverished countries of the world .\n\nThe neutrophil-to-lymphocyte ratio (NLR), and C-reactive protein (CRP) ; has emerged as an important inflammatory markers for cardiovascular risk stratification.\n\nAnd are relatively cheap inflammatory markers, can act as a bridge to mitigate the gap in assessing the cardiovascular risk and outcomes",[27],"2024-07-08",{"date":470,"type":35},"2024-07-09",{"date":472,"type":35},"2024-07-01",{"date":474,"type":21},"2024-12-01",{"name":476,"class":42},"Sohag University",{"id":478,"slug":479,"hasResults":11,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":483,"eligibilityCriteria":484,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":485,"enrollmentInfo":486,"targetDuration":4,"studyType":22,"phases":487,"briefSummary":488,"conditions":489,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":43},"100359104","oct-guided-magmaris-rms-in-stemi-100359104","NCT03955731","OCT Guided Magmaris RMS in STEMI","Optical Coherence Guided Treatment of ST-segment Elevation Myocardial Infarction With the Drug-eluting Resorbable Magnesium Scaffold: the BEST- MAG Multicentre Study. (BElgian ST-segment Elevation Myocardial Infarction Treatment With Resorbable MAGnesium Scaffold).","BESTMAG","Inclusion Criteria:\n\n1. Patients presenting with a ST-elevation myocardial infarction (STEMI) with symptoms onset \\\u003C24 hours or with ongoing symptoms.\n2. Signed patient informed consent.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 or \\> 70 years.\n2. Pregnancy or breastfeeding.\n3. Cardiogenic shock.\n4. Creatinine clearance ≤30 ml\u002Fmin\u002F1.73 m2 (as calculated by MDRD formula for estimated GFR) and not on dialysis. Note: chronic dialysis dependent patients are eligible for enrolment regardless of creatinine clearance.\n5. Infarct-artery reference diameter \\\u003C 2.7 or \\> 4.0 mm (within the segment of the culprit lesion) by visual estimation, and OCT infarct-artery distal reference mean lumen diameter \\\u003C 2.7 or \\> 3.7 mm\n6. Non-optimal vessel preparation after predilatation: residual stenosis \\>30%.\n7. Culprit lesion length \\> 21 mm.\n8. Culprit lesion located within a previously stented segment (stent thrombosis or in-stent restenosis).\n9. Culprit lesion involving a saphenous vein graft.\n10. Culprit lesion involving a bifurcation with an intended two-stent implantation strategy.\n11. Ostial right coronary artery\n12. Severe calcification or tortuosity of the infarct-related artery.\n13. Absolute contraindication to a 12 months dual antiplatelet therapy.\n14. Life expectancy \\\u003C 3 years.\n15. Patients taking oral anticoagulant therapy","70 Years",{"count":178,"type":21},[24],"Percutaneous treatment of coronary artery disease depends on the implantation of stents within diseased coronary segments. Compared with conventional bare-metal and drug- eluting stents, which remain permanently within the coronary anatomy, bioresorbable scaffolds (BRS) offer several potential advantages due to its resorbable properties. The resorbable magnesium scaffold Magmaris has demonstrated favourable outcomes in patients with stable coronary artery disease. In particular, in comparison to polymeric bioresorbable scaffolds, no cases of stent thrombosis have been reported in over two years of follow-up suggesting that magnesium-based resorbable scaffolds have low thrombogenicity and might be particularly beneficial for patients presenting with ST- segment myocardial infarction. A recent pilot study in eighteen patients supports this concept, which has led to the development of the proposed prospective multicentre study including intra-coronary imaging with long-term clinical follow-up.",[27],"2024-07-02",{"date":492,"type":35},"2024-07-03",{"date":494,"type":35},"2019-02-15",{"date":496,"type":21},"2025-02-15",{"name":498,"class":42},"Universitaire Ziekenhuizen KU Leuven",{"id":500,"slug":501,"hasResults":11,"nctId":502,"briefTitle":503,"officialTitle":503,"acronym":4,"eligibilityCriteria":504,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":505,"enrollmentInfo":506,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":508,"conditions":509,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":4},"100552292","predictors-of-thrombus-burden-in-stemi-patients-and-their-impact-on-outcome-100552292","NCT06471192","Predictors of Thrombus Burden in STEMI Patients and Their Impact on Outcome","Inclusion Criteria:\n\n* All patients admitted with STEMI undergoing PPCI will be recruited in the study and the period of data collection will be continued for 12 months. Total number that will be recruited will be at least 200 cases.\n\nExclusion Criteria:\n\n* known chronic inflammatory disease, neoplasms or severe hepatic disease; end-stage renal disorder (estimated glomerular filtration rate \\\u003C 30 ml\u002Fmin\u002F1.73 m2); undergoing renal replacement therapy; no intracoronary lesions shown via angiography; history of cardiac valve surgery; using oral anticoagulants;","90 Years",{"count":507,"type":21},200,"ST-segment elevation myocardial infarction (STEMI) is the most acute manifestation of coronary artery disease and is associated with great morbidity and mortality.(1). High thrombus burden (HTB) during ST-segment elevation myocardial infarction (STEMI) could translate into worse clinical outcomes.(2). HTB has been defined as the occurrence of thrombo- sis during myocardial infarction, as determined by a thrombus score ≥ 3 in the infarct-related artery (IRA) or as a \"cut-off\" occlusion pattern and\u002For large reference vessel diameter (≥ 3.5 mm) in an occluded IRA.(3) Many variables were used to predict the presence of high thrombus burden in STEMI patients undergoing primary PCI. higher C-reactive protein, and low serum albumin, higher C - reactive protein to albumin ratio (4) which can be used as a surrogate marker of pro-inflammation and is closely related to pro-thrombotic state. Furthermore higher neutrophil-lymphocyte ratio is closely associated with HTB and short-term mortality in STEMI patients (5). MAPH score, which is a new score that combines blood viscosity biomarkers such as mean platelet volume (MPV), total protein and hematocrit, can be used to predict thrombus burden in ST-segment elevation myocardial infarction (STEMI) patients.(6). In addition, TyG index, a valid surrogate marker of insulin resistance, is an independent predictor of LTB in STEMI patients who underwent primary PCI and can be used as an indicator of increased intracoronary thrombus burden. (7). Furthermore, Initial troponin level may be associated with larger thrombus burden within a coronary artery. This finding may influence coronary flow and needs to be taken into consideration during primary coronary intervention.(8). The atherogenic index, a logarithmically transformed ratio of molar concentrations of triglycerides to HDL-cholesterol, can be used as a reliable marker for increased coronary thrombus burden, which is associated with adverse cardiovascular outcomes(9).whole blood viscosity has also been showing that WBV at both shear rates is a significant predictor of HTB in NSTEMI patients(10).\n\nIn our research, we aim to study the effect of these different parameters on thrombus burden and their impact on patients outcome at 6 months",[27],"2024-06-18",{"date":512,"type":35},"2024-06-24",{"date":514,"type":21},"2024-07",{"date":516,"type":21},"2025-12",{"name":255,"class":42},{"id":519,"slug":520,"hasResults":11,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":4,"eligibilityCriteria":524,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":199,"enrollmentInfo":525,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":527,"conditions":528,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":4},"100528871","breisgau-pheno-heart-study-100528871","NCT06166407","Breisgau Pheno Heart Study","The Breisgau Pheno Heart Study","Inclusion Criteria:\n\n* Emergency coronary angiography and age\\>18 years and STEMI or NSTEMI or \"none of these diseases\"\n\nExclusion Criteria:\n\n* Hemoglobin\\\u003C7,0 g\u002Fdl\n* Platelets \\\u003C50.000\u002Fµl\n* Unable to provide written informed consent\n* Age \\> 80 years\n* hematological neoplasia\n* metastasized cancers\n* acute infection (z.B. Sepsis)\n* Chronic Inflammatory conditions (z.B. inflammatory bowel disease, Rheumatoid arthritis, chronisch hepatitis)\n* Pregnancy\n* Immunosuppression\n* Resuscitation \\>5 min oder mehr als 1x Defibrillation vor Koronarangiographie\n* Cardiogenic shock\n* Mechanical circulatory support\n* Cardiomyopathy with an left ventricular ejection fraction F \\\u003C40% before the event\n* Dialysis\n* Cirrhosis \\> CHILD-A\n* Not living in the county of Breisgau-Hochschwarzwald or Emmendingen oder planned relocation\n* Alcohol and drug abuse\n* Non-compliance",{"count":526,"type":21},400,"Coronary heart disease and its acute complication, myocardial infarction (MI), represent the leading causes of death in Europe and the United States. Although novel treatment strategies have helped to improve survival in patients with MI, a large proportion of patients develops heart failure and is at risk of life-threatening arrhythmias. Complications arising after MI constitute a severe burden not only for the patients themselves, but also for health care systems worldwide.\n\nThe likelihood of these complications depends on the area of myocardial tissue lost and the process of myocardial repair and scar tissue formation after MI ('remodeling') which are modified by the local and systemic immune response after MI. The immune response is critical after myocardial infarction. In particular, sustained overactive and prolonged inflammatory reactions lead to accentuated myocardial damage and dysfunction. Important mediators of the inflammatory reaction after MI are monocytes, T-cells, B-cells and hematopoietic stem and progenitor cells. Following MI, myeloid cells derived from the hematopoietic system drive a sharp increase in systemic leukocyte levels that correlates closely with mortality. T- and B-cells in particular act in response to specific antigens. Most of the data regarding the inflammatory response after MI, however, are derived from animal models. The immunological phenotypes after MI and their association with clinical outcome in humans are insufficiently characterized.\n\nAims: The aim of this project is to provide establish clinically and immunologically well-characterized cohort of patients after MI This will aid in identifying novel prognostic cellular and humoral biomarkers that may be used to identify patients at a high inflammatory and immune risk and to guide clinical management. Furthermore, these mediators, in the future, may be targeted by novel antigen-specific immunomodulatory approaches.\n\nPatients with myocardial infarction (STEMI and NSTEMI) will be recruited after PCI within 24h and receive a structured follow-up. Clinical read-outs include a detailed and standardized patient history, clinical examination, standard blood work, coronary angiography, ECG, echocardiography and for subgroups, MRI. Patients will present for study visits at 6 weeks, 3 months and 12 months after the initial event. Blood will be sampled at the inclusion and during follow-up visits. Peripheral blood mononuclear cells and plasma will be stored at the Cardiovascular BioBank (CVBB) and FREEZE, both institutions at the University Hospital in Freiburg. Major adverse cardiac events (myocardial infarction, stroke, hospitalization for heart failure, cardiovascular death) will be recorded using telephone interviews and standardized queries to the local authorities. Several laboratory read-outs are planned including flow cytometry, mass cytometry, single cell RNA sequencing, T cell and B cell receptor sequencing and bulk-RNA-sequencing. In an initial approach we aim to recruit 400 patients with MI, of which we expect ≈40 to develop ischemic cardiomyopathy. Differences in immunological profiles between patients that develop MI and a propensity-matched control group will then be analyzed and correlated with clinical outcome data.",[529,27,151],"Myocardial Infarction","2023-12-12",{"date":532,"type":35},"2023-12-19",{"date":534,"type":21},"2024-04",{"date":536,"type":21},"2034-04",{"name":538,"class":42},"University Hospital Freiburg",{"id":540,"slug":541,"hasResults":11,"nctId":542,"briefTitle":543,"officialTitle":543,"acronym":544,"eligibilityCriteria":545,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":548,"conditions":549,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":558,"locationsCount":43},"100438391","optimiser-registry---a-prospective-cohort-study-to-describe-the-optimal-management-and-outcomes-of-patients-presenting-with-acute-myocardial-infarction-100438391","NCT04988672","OPTIMISER Registry - A Prospective Cohort Study to Describe the OPTIMal Management and Outcomes of PatIents PreSEnting With Acute MyocaRdial Infarction","OPTIMISER","Inclusion Criteria:\n\n* Subject \\>18 years of age\n* Individuals who are newly diagnosed with AMI or have been diagnosed with AMI (STEMI or NSTEMI) within the last 5 years (since 2016).\n* Subjects must be willing to sign a patient informed consent (PIC) OR a patient ́s relative\u002F proxy are willing to provide PIC or patients have signed the General Consent (GK).\n\nExclusion Criteria:\n\n* Patient unwilling or unable to provide informed consent\n* Patients with no ACS\u002FAMI (e.g. Takotsubo cardiomyopathy, acute heart failure not related to AMI)",{"count":547,"type":21},4000,"The purpose of the OPTIMISER Registry is to prospectively and retrospectively collect baseline, clinical and procedural data in patients who present with AMI and are treated with PCI as well as prospectively collect the clinical outcome data. Outcomes will be compared in different clinical subgroups. The impact of PCI in AMI in general as well as cardiovascular outcomes after AMI will be assessed.",[529,550,27,151],"Myocardial Ischemia","2023-10-04",{"date":553,"type":35},"2023-10-06",{"date":555,"type":35},"2021-01-01",{"date":557,"type":21},"2030-12-31",{"name":559,"class":42},"Luzerner Kantonsspital",{"id":561,"slug":562,"hasResults":11,"nctId":563,"briefTitle":564,"officialTitle":564,"acronym":565,"eligibilityCriteria":566,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":567,"targetDuration":4,"studyType":22,"phases":569,"briefSummary":570,"conditions":571,"keywords":574,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":578,"lastUpdatePostDateStruct":579,"startDateStruct":581,"completionDateStruct":582,"leadSponsor":584,"locationsCount":4},"100469495","upfront-premedication-for-reduction-of-microvascular-obstruction-and-no-reflow-in-treating-st-segment-elevation-myocardial-infarction-100469495","NCT05393557","Upfront Premedication For Reduction of Microvascular Obstruction and No-reflow in Treating ST-segment Elevation Myocardial Infarction","UPFRONT-STEMI","Inclusion Criteria:\n\n* STEMI patients with time from symptom onset of \\\u003C 24 hours duration.\n* Large thrombus burden confirmed after initial wiring.\n* Radial vascular access.\n\nExclusion Criteria:\n\n* STEMI patients receiving successful fibrinolytic therapy.\n* TIMI flow ≥ 1 or TIMI thrombus grade ≤ 3 at initial wiring.\n* Refusal to participate int the study, or unable to be consented (unconscious or comatose patients).\n* Femoral access.\n* Previous infarction in the same territory.\n* Patients receiving PTCA only for acute reperfusion and planned for CABG.\n* Patients with known intolerance or contraindications for CMR, such as claustrophobic or those with mechanical heart valve prothesis, or implantable non-conditional heart rhythm devices.",{"count":568,"type":21},626,[24],"Angiographic no-reflow during primary PCI procedures occurs at relatively high rate (25%) and is associated with worsening of long term morbidity and mortality. The exact mechanism of no-reflow is not fully understood, yet it is believed to be multifactorial including microvascular plugging with activated platelets and thrombotic debris in addition to the microvascular dysfunction from the ischaemia-reperfusion injury.\n\nDespite a theoretical advantage of glycoprotein IIb\u002FIIIa inhibitors (GPi) (like; Tirofiban) to suppress the intense platelets' activation\u002Freaction; their use did not lead to a significant net benefit, because it was opposed by increased risk of bleeding.\n\nHowever, the bleeding that plagued GPi use was predominantly related to vascular access in the era femoral approach was the default. Moreover, there are some recent data suggesting that small intracoronary bolus of GPi was non-inferior to intravenous bolus-infusion dose with less bleeding events.\n\nThis study plans to assess upfront premedication with small doses of GPi + Nitroglycerin ± Verapamil, with staged restoration of flow (repeated balloon inflation) to reduce angiographic no-reflow and CMR assessed microvascular occlusion (MVO).",[27,572,573],"Large Thrombus Burden","No-Reflow Phenomenon",[238,27,575,576,577],"Glycoprotein inhibitor","repeated intermittent balloon inflation","reperfusion injury","2023-08-30",{"date":580,"type":35},"2023-08-31",{"date":296,"type":21},{"date":583,"type":21},"2026-11-30",{"name":585,"class":42},"Cairo University",{"id":587,"slug":588,"hasResults":11,"nctId":589,"briefTitle":590,"officialTitle":590,"acronym":4,"eligibilityCriteria":591,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":592,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":594,"conditions":595,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":604,"completionDateStruct":606,"leadSponsor":608,"locationsCount":610},"100268807","france-pci-registry--national-observatory-of-interventional-cardiology-100268807","NCT02778724","France PCI Registry : National Observatory of Interventional Cardiology","Inclusion Criteria:\n\n* Age =\\>18 years at enrollment\n* Patient who have had a coronary angiogram or angioplasty\n\nExclusion Criteria:\n\n* Patient who didn't want to participated",{"count":593,"type":21},40000,"Rigorous clinical practice assessment is a key factor to improve patient's care and prognosis in interventional cardiology (IC). A multicentric IC observational study (CRAC), fully integrated to usual coronary activity report software, started in Centre Val de Loire (CVL) region in 2014.\n\nCRAC observatory was conduced on five IC CathLab of CVL region. Quality of collected data is regularly evaluated and allowed building an exhaustive, and reliable database. This solution could easily be developed in other French regions.",[596,597,598,599,27,600],"Interventional","Cardiology","Angioplasty","Coronary","Database","2022-03-29",{"date":603,"type":35},"2022-04-07",{"date":605,"type":4},"2014-01",{"date":607,"type":21},"2030-12",{"name":609,"class":42},"Club Régional des Angioplasticiens de la région Centre",15,{"id":612,"slug":613,"hasResults":11,"nctId":614,"briefTitle":615,"officialTitle":616,"acronym":617,"eligibilityCriteria":618,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":619,"enrollmentInfo":620,"targetDuration":4,"studyType":22,"phases":622,"briefSummary":623,"conditions":624,"keywords":625,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":630,"lastUpdatePostDateStruct":631,"startDateStruct":633,"completionDateStruct":635,"leadSponsor":636,"locationsCount":43},"100432519","phase-3-the-effects-of-sacubitril-valsartan-vs-enalapril-on-left-ventricular-remodeling-in-st-elevation-myocardial-infarction-100432519","NCT04912167","The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction","A Multi-center, Prospective Randomized Controlled Trial on the Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction","PERI-STEMI","Inclusion Criteria:\n\n* Aged between 18 - 75 years old\n* First-time ST-segment elevation myocardial infarction based on the newest ESC guidelines\n* Timely primary percutaneous coronary intervention within 12 hours from onset\n* Written informed consent acquired\n\nExclusion Criteria:\n\n* Known history of or persistent clinical chronic heart failure prior to randomization\n* Previous use of ARNI, or intolerance or contraindications to study drugs including ARNI or ACEI\n* History of significant chronic coronary obstruction and adverse ventricular remodeling\n* History of any cardiomyopathy, valvular heart disease, congenital heart disease, stent or CABG, or planned open-heart surgery within 3 months\n* History of hepatic impairment or history of cirrhosis with evidence of portal hypertension\n* History of chronic renal dysfunction, or eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m2\n* History of malignancy and with a life span less than one year\n* Patients with a known history of angioedema related to previous ACEIs\u002FARB therapy.\n* With contraindication to MRI examination (pacemaker and claustrophobia) or cannot finish breath-holding when lying on the examination bed\n* Pregnancy or nursing women","75 Years",{"count":621,"type":21},376,[147],"The primary objective of the PERI-STEMI trial is to assess whether sacubitril-valsartan is more effective in preventing adverse LV remodeling for patients with ST-elevation myocardial infarction (STEMI) than enalapril.",[27],[626,627,628,629],"ST-elevation myocardial infarction (STEMI)","cardiovascular magnetic resonance (CMR)","angiotensin receptor neprilysin inhibitor (ARNI)","angiotensin-converting enzyme inhibitor (ACEI)","2021-09-23",{"date":632,"type":35},"2021-09-29",{"date":634,"type":21},"2021-11",{"date":133,"type":21},{"name":637,"class":42},"West China Hospital"]